Aberrant Signaling Pathways in Glioma
暂无分享,去创建一个
Mitsutoshi Nakada | J. Hamada | M. Nakada | Takuya Watanabe | Y. Hayashi | Daisuke Kita | Lei Teng | L. Teng | Yutaka Hayashi | Takuya Watanabe | Jun-Ichiro Hamada | I. V. Pyko | Ilya V. Pyko | D. Kita
[1] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[2] J. Romashkova,et al. NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.
[3] C. James,et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.
[4] Paul S Mischel,et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.
[5] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[6] J. Gills,et al. Perifosine: Update on a novel Akt inhibitor , 2009, Current oncology reports.
[7] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[8] Hongye Liu,et al. Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.
[9] Roger E. McLendon,et al. Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth , 2010, PLoS biology.
[10] S. Hubbard. Structural analysis of receptor tyrosine kinases. , 1999, Progress in biophysics and molecular biology.
[11] D. Brat,et al. Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression , 2003, Annals of Internal Medicine.
[12] M. Berger,et al. EGFR overexpression and radiation response in glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.
[13] K. Sekiguchi,et al. Integrin α3β1‐mediated interaction with laminin‐5 stimulates adhesion, migration and invasion of malignant glioma cells , 1998 .
[14] D. Louis,et al. Mutation analysis of the hCHK2 gene in primary human malignant gliomas , 2000, Neurogenetics.
[15] R. Kiss,et al. Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features , 2001, Glia.
[16] P. Kleihues,et al. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome , 2009, Acta Neuropathologica.
[17] Dirk Troost,et al. Absence of AKT1 Mutations in Glioblastoma , 2009, PloS one.
[18] J. Folkman,et al. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. , 1977, Microvascular research.
[19] J. Takahashi,et al. Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor , 1991, FEBS letters.
[20] M. Katsuki,et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells , 1999, The EMBO journal.
[21] F. Davis,et al. Epidemiology of brain tumors. , 2000, Current opinion in neurology.
[22] P. Keegan,et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.
[23] K. Plate,et al. Angiogenesis in malignant gliomas , 1995, Glia.
[24] Manuel Hidalgo,et al. Intracellular signal transduction pathway proteins as targets for cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] F. Zindy,et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] L. Puricelli,et al. CD44 expression in human gliomas , 2002, Journal of surgical oncology.
[27] D. Viskochil,et al. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. , 2010, Neurosurgical focus.
[28] R. Stupp,et al. 2010: neuro-oncology is moving! , 2010, Current opinion in neurology.
[29] Chitra Sarkar,et al. Apoptosis and proliferation: correlation with p53 in astrocytic tumours , 2005, Journal of Neuro-Oncology.
[30] J. Romashkova,et al. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. , 1999, Nature.
[31] Ralph Weissleder,et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. , 2007, Cancer research.
[32] D. Louis,et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.
[33] P. Wen,et al. Antiangiogenic strategies for treatment of malignant gliomas , 2009, Neurotherapeutics.
[34] P. Jeggo,et al. Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner , 2002, Molecular and Cellular Biology.
[35] M. Weller,et al. PIK3CA alterations in primary (de novo) and secondary glioblastomas , 2007, Acta Neuropathologica.
[36] G. Palade,et al. Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.
[37] Eric C. Holland,et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.
[38] Markus Bredel,et al. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas , 1999, Brain Research Reviews.
[39] M. J. van den Bent,et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma , 2009, British Journal of Cancer.
[40] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[41] C. Brennan,et al. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. , 2010, Cancer cell.
[42] C. Heldin,et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.
[43] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[44] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] H. Lodish,et al. Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.
[46] M. Berens,et al. Molecular targets of glioma invasion , 2007, Cellular and Molecular Life Sciences.
[47] A. Aguzzi,et al. IL-6 is required for glioma development in a mouse model , 2004, Oncogene.
[48] M. Kojima,et al. Clinical importance of c-Met protein expression in high grade astrocytic tumors. , 1998, Neurologia medico-chirurgica.
[49] S. Franceschi,et al. Age as a Predictive Factor in Glioblastomas: Population-Based Study , 2009, Neuroepidemiology.
[50] D. Steindler,et al. Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.
[51] Erwin G. Van Meir,et al. Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma , 2010, CA: a cancer journal for clinicians.
[52] A. Hall,et al. Rho GTPases in cell biology , 2002, Nature.
[53] P. Kleihues,et al. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas , 1997, International journal of cancer.
[54] M. Israel,et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.
[55] P. Kleihues,et al. Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas , 2004, Brain pathology.
[56] Alessia Pica,et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] David J. Anderson,et al. Development of NG2 neural progenitor cells requires Olig gene function , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[58] M. Weller. Angiogenesis in glioblastoma: just another moving target? , 2010, Brain : a journal of neurology.
[59] D. Louis,et al. Molecular Genetic Correlates of p16, cdk4, and pRb Immunohistochemistry in Glioblastomas , 1998, Journal of neuropathology and experimental neurology.
[60] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[61] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[62] K. Kinzler,et al. The molecular basis of Turcot's syndrome. , 1995, The New England journal of medicine.
[63] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] B. Bejcek,et al. NF-kappaB controls growth of glioblastomas/astrocytomas. , 2008, Molecular and cellular biochemistry.
[65] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[66] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[67] M. Shibuya,et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors , 1988, Molecular and cellular biology.
[68] J. Petrini,et al. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. , 2009, DNA repair.
[69] Yasuhiro Yonekawa,et al. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas , 1997, Acta Neuropathologica.
[70] M. J. van den Bent,et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.
[71] W. Cavenee,et al. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. , 1998, Cancer research.
[72] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[73] D. Zagzag,et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. , 1996, Cancer research.
[74] Frank McCormick,et al. The GTPase superfamily: conserved structure and molecular mechanism , 1991, Nature.
[75] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[76] D. Stephenson,et al. Recent developments in neurofibromatosis type 1 , 2007, Current opinion in neurology.
[77] F. White,et al. Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach , 2007, Cell cycle.
[78] S. Sorscher. EGFR mutations and sensitivity to gefitinib. , 2004, The New England journal of medicine.
[79] B. Bejcek,et al. NF-κB controls growth of glioblastomas/astrocytomas , 2007, Molecular and Cellular Biochemistry.
[80] K. Sekiguchi,et al. Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. , 1998, International journal of cancer.
[81] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[82] E. Appella,et al. p53 transcriptional activity is essential for p53‐dependent apoptosis following DNA damage , 2000, The EMBO journal.
[83] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[84] W Arap,et al. Loss of P16INK4 expression is frequent in high grade gliomas. , 1995, Cancer research.
[85] Allan H Friedman,et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] C. Beaudry,et al. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. , 2005, Cancer research.
[87] Gordon Mills,et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC , 1998, Current Biology.
[88] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[89] T. McDonnell,et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. , 1997, Journal of the National Cancer Institute.
[90] M. Nakao,et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration , 1999, Oncogene.
[91] Y. Yonekawa,et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.
[92] P. Meltzer,et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. , 1994, Cancer research.
[93] M. Oren,et al. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.
[94] G. Bernier,et al. BMI1 Sustains Human Glioblastoma Multiforme Stem Cell Renewal , 2009, The Journal of Neuroscience.
[95] A Guha,et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.
[96] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[97] David N Louis,et al. Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.
[98] Tracy T Batchelor,et al. Angiogenesis as a therapeutic target in malignant gliomas. , 2009, The oncologist.
[99] P. Echlin,et al. Amplification and overexpression of the EGF receptor gene in primary human glioblastomas , 1985 .
[100] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[101] Kimmo J Hatanpaa,et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.
[102] P. Workman,et al. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. , 2004, Biochemical Society transactions.
[103] K. Ichimura,et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.
[104] Yunqing Li,et al. The Neuronal MicroRNA miR-326 Acts in a Feedback Loop with Notch and Has Therapeutic Potential against Brain Tumors , 2009, The Journal of Neuroscience.
[105] M. Shibuya. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor , 2009, The FEBS journal.
[106] M. Oren,et al. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.
[107] P. Echlin,et al. Amplification and Overexpression of the EGF Receptor Gene in Primary Human Glioblastomas , 1985, Journal of Cell Science.
[108] M. J. van den Bent,et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] Guido Nikkhah,et al. NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts , 2009, Stem cells.
[110] P. Wen,et al. Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.
[111] O D Laerum,et al. Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. , 1990, Cancer research.
[112] Yunqing Li,et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells , 2010, Cell cycle.
[113] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[114] Susan M. Chang,et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.
[115] A. Guha,et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.
[116] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[117] A. Olivi,et al. Cyclopamine‐Mediated Hedgehog Pathway Inhibition Depletes Stem‐Like Cancer Cells in Glioblastoma , 2007, Stem cells.
[118] D. Durocher,et al. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? , 2001, Current opinion in cell biology.
[119] H. von Holst,et al. Characterization of insulin-like growth factor 1 in human primary brain tumors. , 1993, Cancer research.
[120] P. Kleihues,et al. The p53 gene and its role in human brain tumors , 1995, Glia.
[121] Michael E. Berens,et al. Glioma Cell Motility is Associated with Reduced Transcription of Proapoptotic and Proliferation Genes: A cDNA Microarray Analysis , 2001, Journal of Neuro-Oncology.
[122] S. Artavanis-Tsakonas,et al. Notch signaling: cell fate control and signal integration in development. , 1999, Science.
[123] H. Saya,et al. Mechanism and biological significance of CD44 cleavage , 2004, Cancer science.
[124] D. Louis,et al. Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme , 1997, Brain pathology.
[125] Alejandra Bruna,et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.
[126] Y. Yonekawa,et al. p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas , 2001, Brain pathology.
[127] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[128] Y. Yonekawa,et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[129] A. Godwin,et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. , 2002, The American journal of pathology.
[130] P. Kleihues,et al. Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.
[131] W. Paulus,et al. Diffuse brain invasion of glioma cells requires beta 1 integrins. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[132] G. Kapoor,et al. Mitogenic signaling cascades in glial tumors. , 2003, Neurosurgery.
[133] M. Essig,et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[134] M. Westphal,et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[135] A. Yu,et al. Tumor Necrosis Factor‐α and Basic Fibroblast Growth Factor Decrease Glial Fibrillary Acidic Protein and Its Encoding mRNA in Astrocyte Cultures and Glioblastoma Cells , 1995, Journal of neurochemistry.
[136] C. Brennan,et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. , 2010, Cell stem cell.
[137] E. Oldfield,et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.
[138] M. Platten,et al. Malignant glioma biology: Role for TGF‐β in growth, motility, angiogenesis, and immune escape , 2001 .
[139] Daniel J. Hoeppner,et al. Notch signalling regulates stem cell numbers in vitro and in vivo , 2006, Nature.
[140] S. Elledge,et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.
[141] S. Vandenberg,et al. PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling , 2006, Neuron.
[142] Ugo Orfanelli,et al. Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.
[143] Johanna Schleutker,et al. CHEK2 mutations in primary glioblastomas , 2005, Journal of Neuro-Oncology.
[144] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[145] K. Kinzler,et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[146] J. Gu,et al. JSI-124 inhibits glioblastoma multiforme cell proliferation through G2/M cell cycle arrest and apoptosis augmentation , 2008, Cancer biology & therapy.
[147] M. Nagane. Neuro-oncology: continuing multidisciplinary progress , 2011, The Lancet Neurology.
[148] J. Bruner,et al. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. , 1994, Cancer research.
[149] P. Kleihues,et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.
[150] C. Heldin,et al. Platelet‐derived growth factor in human glioma , 1995, Glia.
[151] G. Kapoor,et al. Receptor Tyrosine Kinase Signaling In Gliomagenesis: Pathobiology And Therapeutic Approaches , 2003, Cancer biology & therapy.
[152] K. Nikolich,et al. Discoidin Domain Receptor-1a (DDR1a) Promotes Glioma Cell Invasion and Adhesion in Association with Matrix Metalloproteinase-2 , 2006, Journal of Neuro-Oncology.
[153] Mitchel S Berger,et al. Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.
[154] Y. Yonekawa,et al. PTEN (MMAC1) Mutations Are Frequent in Primary Glioblastomas (de novo) but not in Secondary Glioblastomas , 1998, Journal of neuropathology and experimental neurology.
[155] G. Reifenberger,et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.
[156] Paola Pisani,et al. Genetic Pathways to Glioblastoma , 2004, Cancer Research.
[157] D. Leroith,et al. Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.
[158] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[159] Peter G Schultz,et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. , 2010, Cell stem cell.
[160] Renzo Boldorini,et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. , 2006, Cancer research.
[161] Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics , 2010, Molecular Cancer.
[162] M. Ahluwalia,et al. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. , 2010, Cancer letters.
[163] T. Kishimoto. Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.
[164] T. Shaikh,et al. Duplication of 7q34 in Pediatric Low‐Grade Astrocytomas Detected by High‐Density Single‐Nucleotide Polymorphism‐Based Genotype Arrays Results in a Novel BRAF Fusion Gene , 2009, Brain pathology.
[165] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[166] A. Pawson,et al. Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.
[167] Andreas S. Beutler,et al. Diffuse brain invasion of glioma cells requires β1 integrins , 1996 .
[168] A. Kaye,et al. Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas , 2009, Journal of Clinical Neuroscience.
[169] Arata Tomiyama,et al. Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self‐Renewal and Tumorigenicity of Glioblastoma Stem‐Like Cells , 2010, Stem cells.
[170] S. Leung,et al. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation , 2000, Oncogene.
[171] S. Söldner-Rembold,et al. The first 30 years , 1983 .
[172] I. Date,et al. Angiogenesis and invasion in glioma , 2011, Brain Tumor Pathology.
[173] K. Alitalo,et al. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[174] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[175] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[176] G. Broggi,et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma , 2003, Journal of Neuro-Oncology.
[177] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[178] Yuri Kotliarov,et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. , 2008, Cancer cell.
[179] M. Kuwano,et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. , 2005, Cancer research.
[180] F. DiMeco,et al. Erratum: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma (Cancer Research (October 2004) 64 (7011-7021) , 2004 .
[181] G. Reifenberger,et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.
[182] K. Miyazono,et al. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. , 1993, Oncogene.
[183] P. Kleihues,et al. Genetic alterations and signaling pathways in the evolution of gliomas , 2009, Cancer science.
[184] R. Baserga,et al. The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.
[185] R. Reis,et al. Mutation analysis of B-RAF gene in human gliomas , 2005, Acta Neuropathologica.
[186] J. Folkman. Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.
[187] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[188] Y. Shiloh. ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.
[189] J. S. Rao,et al. Molecular mechanisms of glioma invasiveness: the role of proteases , 2003, Nature Reviews Cancer.
[190] Daniel H. Geschwind,et al. Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[191] Nicole Rusk,et al. Role of Synaptojanin 2 in Glioma Cell Migration and Invasion , 2004, Cancer Research.
[192] Y. Marie,et al. A New Alternative Mechanism in Glioblastoma Vascularization: Tubular Vasculogenic Mimicry , 2022 .
[193] A. Ullrich,et al. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. , 2001, Endocrine-related cancer.
[194] C. D. Edwards,et al. A novel p16INK4A transcript. , 1995, Cancer research.
[195] Kevin Ryan,et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.